Kim Seung Tai, Jung Chul Won, Lee Jeeyun, Kwon Jung Mi, Oh Sung Young, Park Byeong-Bae, Lee Hyo Rak, Kim Hyun Jung, Kim Kihyun, Kim Won Seog, Ahn Jin Seok, Kang Won Ki, Park Keunchil
Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Leuk Lymphoma. 2007 May;48(5):937-43. doi: 10.1080/10428190701223309.
The medical records of 99 patients with acute myeloid leukemia (AML; except AML, M3) in the first remission from 1995 to 2004 were retrospectively reviewed. When they achieved complete remission, at first complete remission (CR1), patients received allogeneic (n = 23), autologous hematopoietic stem cell transplantation (HSCT) (n = 35), or intensive chemotherapy (n = 41) according to prognostic factors and donor availability. There was an advantage in terms of event-free survival (EFS, p = 0.0001) and overall survival (OS, p = 0.0002) with HSCT as compared to those of intensive chemotherapy. However, the EFS and OS were not different between allogeneic HSCT and autologous HSCT. In high-risk patients, the EFS and OS of allogenic or autologous HSCT group were higher compared with those in the intensive chemotherapy group (p < 0.01). However, there was no difference between allogeneic HSCT and autologous HSCT in terms of EFS and OS. In the intermediate- or low-risk group, there was no significant difference in the outcome according to the postremission modalities.
回顾性分析了1995年至2004年期间99例首次缓解的急性髓系白血病（AML；M3型除外）患者的病历。患者达到完全缓解时，即首次完全缓解（CR1）时，根据预后因素和供体可用性，接受了异基因造血干细胞移植（n = 23）、自体造血干细胞移植（HSCT）（n = 35）或强化化疗（n = 41）。与强化化疗相比，HSCT在无事件生存期（EFS，p = 0.0001）和总生存期（OS，p = 0.0002）方面具有优势。然而，异基因HSCT和自体HSCT之间的EFS和OS并无差异。在高危患者中，异基因或自体HSCT组的EFS和OS高于强化化疗组（p < 0.01）。然而，异基因HSCT和自体HSCT在EFS和OS方面并无差异。在中危或低危组中，缓解后治疗方式的结局无显著差异。
